SEC Tracker
Get the app
PPCB · XBRL financial data

Propanc Biopharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PPCB's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024†Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Research and development161146552*62545454*6020170376*
General and administrative394318349193*22115453,0683,585*4,5993,6286,220(13,776)*
Total operating expenses417438421260*29121353,1293,645*4,6743,6556,4003,457*
Operating income (loss)(417)(438)(421)(260)*(291)(213)(53,129)(3,645)*(4,674)(3,655)(6,400)(3,457)*
Interest expense17826413390*86119104255*306593828*
Other income (expense)——————————435*
Income tax expense (benefit)—(129)(0)(0)*————————
Net income (loss)(351)(584)(527)(359)*(354)(430)(54,067)(4,071)*(4,838)(3,091)(6,360)(4,573)*
Earnings per share, basic USD per share(0.04)(0.03)(0.01)—0.00(32.23)(12.50)—(0.39)(0.30)(0.28)—
Earnings per share, diluted USD per share(0.04)(0.03)(0.01)—0.00(32.23)(12.50)—(0.39)(0.30)(0.28)—
Weighted average shares, basic thousands of shares10,99023,81359,640—590,937134,326—12,33213,36022,427—
Weighted average shares, diluted thousands of shares10,99023,81359,640—590,937134,326—12,33213,36022,427—
  • † Share count changed about 4x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/51386 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 755x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/9 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (PPCB's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024†Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Cash and cash equivalents7726219155112603561444832
Prepaid and other current assets20121191——————
Total current assets146211132522189,7368,3538,7637,7078,2238,543
Property and equipment, net00——————2444
Right-of-use asset———18———5956514741
Total assets1802423772647922,52719,63217,97615,11214,33412,780
Accounts payable1,0811,1581,1881,2131,2391,2231,1221,2501,0729579741,131
Total current liabilities3,1333,7623,6883,7934,1014,1554,3415,5783,5723,6243,4763,354
Lease liability, non-current———————4242353024
Total liabilities3,1703,8063,7373,8514,1724,2374,4355,7263,6153,6593,5063,378
Accumulated deficit(65,178)(65,797)(66,340)(66,698)(67,053)(67,483)(121,550)(125,622)(130,459)(134,483)(140,843)(144,484)
Total stockholders' equity(2,989)(3,564)(3,700)(3,779)(4,108)(4,159)18,09213,90614,36110,4529,8289,402
Total liabilities and equity1802423772647922,52719,63217,97615,11214,33412,780
Common shares outstanding (cover page) thousands of shares22,25952,145167,979688,022789,8991511,61212,80713,36415,85956,9596,331
  • † Share count changed about 4x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/51386 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 755x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/9 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (PPCB's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024†Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Net income (loss)(351)(584)(527)(359)*(354)(430)(54,067)(4,071)*(4,838)(3,091)(6,360)(4,573)*
Stock-based compensation———————3,116*3,0252,472*1,774*1,228*
Net cash from operating activities(333)(239)*(103)*(260)*(236)(6)*(136)*(27)*(1,939)(999)*(1,142)*(1,602)*
Purchases of property and equipment————————22*0*0*
Net cash from investing activities————————(2)(2)*(0)*(0)*
Proceeds from issuing common stock———12*————3,3140*0*0*
Net cash from financing activities350274*67*251*21680*187*8*2,527965*982*1,984*
Net change in cash(3)65*(65)*15*(12)5*36*(39)*591(42)*(118)*388*
  • † Share count changed about 4x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/51386 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 755x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/9 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Propanc Biopharma832not reported(1,602)*6.3M0.5 quarters 10-KJun 30, 2026
Cannapharmarx0.6276(127)*708.7M0.0 quarters 10-QJun 30, 2026
MetaVia12,634not reported(3,762)*6.6M3.4 quarters 10-QJun 30, 2026
Oragenics3,864not reported(2,187)*4.5M1.8 quarters 10-QJun 30, 2026
Inhibitor Therapeutics516not reported(775)*173.8M0.7 quarters 10-QJun 30, 2026
PTC Therapeutics508,894357,807(25,311)*83.5M— 10-QSep 30, 2026
Integrated Biopharma4,471not reported(1,194)*31.1M3.7 quarters 10-KJun 30, 2026
Nomad Power Solutions12,670not reported(1,612)*16.1M7.9 quarters 10-QJun 30, 2026
Enveric Biosciences8,296not reported(2,445)*4.5M3.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.